Valuation: Cosmos Holdings Inc.

Market Cap 10.99M 9.43M 8.81M 8.08M 15.19M 1.05B 15.44M 104M 40.69M 527M 41.28M 40.38M 1.74B P/E 2026 *
-0.92x
P/E 2027 * 2.76x
Enterprise Value 10.99M 9.43M 8.81M 8.08M 15.19M 1.05B 15.44M 104M 40.69M 527M 41.28M 40.38M 1.74B EV / Sales 2026 *
0.14x
EV / Sales 2027 * 0.1x
Free-Float
78.25%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 2016-02-25
Director of Finance/CFO 43 2020-11-10
Chief Operating Officer 56 2023-01-31
Director TitleAgeSince
Director/Board Member 58 2014-01-12
Chairman 60 2016-02-25
Director/Board Member 59 2016-11-17
Change 5-day change 1-year change 3-year change Capi.($)
-5.65%-2.45% - - 10.99M
-1.79%-2.85%+26.12%+103.06% 99.53B
-0.06%+0.29%+57.60%+173.56% 54.62B
0.00%-2.68%+2.47%+279.08% 23.75B
-0.37%-1.15%-13.43%-14.96% 8.13B
-1.52%-3.39%-37.95%-24.26% 7.42B
-0.72%-0.78%-15.73%-23.46% 6.66B
-2.05%-0.57%+7.35%+22.03% 6.55B
-0.15%-0.25%-5.28%+15.71% 5.03B
+0.56%+2.49%+7.52%+17.77% 3.71B
Average -1.18%-0.62%+3.19%+60.95% 23.93B
Weighted average by Cap. -0.99%-1.57%+24.87%+121.61%

Financials

2026 *2027 *
Net sales 80.8M 69.31M 64.72M 59.38M 112M 7.72B 113M 764M 299M 3.87B 303M 297M 12.81B 111M 95.04M 88.75M 81.43M 153M 10.59B 156M 1.05B 410M 5.31B 416M 407M 17.56B
Net income - -
Net Debt - -
Logo Cosmos Holdings Inc.
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
Employees
-

Quarterly revenue - Rate of surprise